The future perspectives in transrectal prostate ultrasound guided biopsy - Abstract

Prostate cancer is one of the most common neoplasms in men.

Transrectal ultrasound (TRUS)-guided systematic biopsy has a crucial role in the diagnosis of prostate cancer. However, it shows limited value with gray-scale ultrasound alone because only a small number of malignancies are visible on TRUS. Recently, new emerging technologies in TRUS-guided prostate biopsy were introduced and showed high potential in the diagnosis of prostate cancer. High echogenicity of ultrasound contrast agent reflect the increased status of angiogenesis in tumor. Molecular imaging for targeting specific biomarker can be also used using ultrasound contrast agent for detecting angiogenesis or surface biomarker of prostate cancer. The combination of TRUS-guided prostate biopsy and ultrasound contrast agents can increase the accuracy of prostate cancer diagnosis. Elastography is an emerging ultrasound technique that can provide the information regarding tissue elasticity and stiffness. Tumors are usually stiffer than the surrounding soft tissue. In two types of elastography techniques, shearwave elastography has many potential in that it can provide quantitative information on tissue elasticity. Multiparametric magnetic resonance imaging (MRI) from high resolution morphologic and functional magnetic resonance (MR) technique enables to detect more prostate cancers. The combination of functional techniques including apparent diffusion coefficient map from diffusion weighted imaging, dynamic contrast enhanced MR and MR spectroscopy are helpful in the localization of the prostate cancer. MR-ultrasound (US) fusion image can enhance the advantages of both two modalities. With MR-US fusion image, targeted biopsy of suspicious areas on MRI is possible and fusion image guided biopsy can provide improved detection rate. In conclusion, with recent advances in multiparametric-MRI, and introduction of new US techniques such as contrast-enhanced US and elastography, TRUS-guided biopsy may evolve toward targeted biopsies rather than systematic biopsy for getting information reflecting the exact status of the prostate.

Written by:
Hwang SI, Lee HJ.   Are you the author?
Department of Radiology, Seoul National University College of Medicine, Seoul, Korea; Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Korea; Department of Radiology, Seoul National University College of Medicine, Seoul, Korea; Kidney Research Institute, Seoul National University College of Medicine, Seoul, Korea; Department of Nanoconvergence, Seoul National University Graduate School of Convergence Science and Technology, Suwon, Korea.

Reference: Prostate Int. 2014 Dec;2(4):153-60.
doi: 10.12954/PI.14062

PubMed Abstract
PMID: 25599070 Prostate Cancer Section